Search
TD-0903
go.drugbank.com/drugs/DB16463InvestigationalTD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants … with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)
UC-781
go.drugbank.com/drugs/DB05871InvestigationalUC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.
Cefadroxil
go.drugbank.com/drugs/DB01140ApprovedInvestigationalVet approvedWithdrawnLong-acting, broad-spectrum, water-soluble, cephalexin derivative.
ISIS 325568
go.drugbank.com/drugs/DB06099InvestigationalIt was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.
Pegdinetanib
go.drugbank.com/drugs/DB05931InvestigationalCT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationaldiphtheriae* grown in another culture. … Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Raseglurant
go.drugbank.com/drugs/DB05070InvestigationalThe orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.
Etizolam
go.drugbank.com/drugs/DB09166InvestigationalInitially introduced in 1983 in Japan as treatment for neurological conditions such as anxiety and sleep disorders, etizolam is marketed in Japan, Italy and India. … It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.
International brands: E1Melperone
go.drugbank.com/drugs/DB09224InvestigationalIt has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. … Melperone has been used for a span of greater than 30 years in the European Union [L1316].